Welcome to the website of Michael Schlander,
- Professor of Health Economics at the University of Heidelberg
and - Head of Division of Health Economics at German Cancer Research Center (DKFZ)
- Founder and Chairman of InnoValHC,
Institute for Innovation & Valuation in Health Care
[founding member, Alliance for the Advancement of Applied Health Economics, A3HE]
News
2025
OECI 2025 Oncology Days
Michael Schlander will speak at the OECI 2025 Oncology Days, which will take place in Athens / Greece from June 11-13. His presentation will focus on the topic "Socioeconomic Impact Analysis: «Towards A More Comprehensive Patient Perspective» | Linking Research & Policy".
Pharma Pricing & Access Innovation Conference 2025
Michael Schlander is invited as a speaker to the PPIC | Pharma Pricing & Access Innovation Conference in Basel / Switzerland from June 03-05, and he will present under the heading ´Early Strategic Decision Making in Drug Development: The Role of Health Economics for Market Access´ - exploring the strategic importance and benefits of early advise consultations for pharmaceutical manufacturers. His focus will be on the national HTA agencies G-BA (Germany), HAS (France) and NICE (England and Wales) with examples of global trends. Topics will include the choice of surrogate endpoints and targeted subpopulations for HTAs, and the optimal use of patient reported outcomes (PROs) data in the context of international HTA trends, including the relevance of socioeconomic burden.
Should new drug prices be based on cost?
Michael Schlander will attend the Conference «L’insoutenabilité, un défi incontournable pour l’avenir de la cancérologie», which will take place in Lyon / France on May 21 & 22, 2025, and he will present the topic "Should new drug prices be based on cost?".
Scientific Contributions to ISPOR 2025 Conference
Michael Schlander will attend the ISPOR 2025 Conference in Montreal, QC / Canada from May 13-16, and he will have scientific contributions on ´The Socioeconomic Impact of Cancer and Cancer Care on Patients and Their Relatives: Assessing the Content Validity of Dedicated Patient-Reported Outcomes Measurement (PROM) Instruments´ and ´More than “Financial Toxicity”: The Socioeconomic Impact of Cancer and Cancer Care on Patients and Their Relatives´.
Heidelberg Health Economics Summer School 2025 - "Early Bird Registration"
The Heidelberg Health Economics Summer School 2025 - offered by the the Institute for Innovation & Valuation in Health Care (InnoValHC) under the auspices of the Ruprecht-Karls-University Heidelberg - will be an unsurpassed opportunity to meet leading experts in health policy and economics, and to discuss with them about key challenges and potential solutions in the context of economic evaluation for use in health technology assessments (HTAs) to inform patient access, pricing, and reimbursement decisions, including implications for research and development (R&D).
Again, this year´s Summer School will comprise two modules and will take place at the NOBIS event center in Bruneck, South Tyrol / Italy.
For more detailed information please visit the Institute´s website.
Heidelberg Health Economics Summer School 2024 - Evaluation
The Heidelberg Health Economics Summer School 2024, a high-level, full week program offered by the the Institute for Innovation & Valuation in Health Care (InnoValHC) under the auspices of the Ruprecht-Karls-University Heidelberg, addressed the role of (health) economic evaluation in the regulatory context of formal Health Technology Assessments (HTAs).
The Summer School took place at NOBIS / NOI Techpark in Bruneck-Brunico / Italy from September 23-27, 2024; for more detailed information - including the formal Evaluation Report, please visit the InnoValHC website.